In yet another move reinforcing the increasing need for careful management of its operations, Alliança Saúde announced on the morning of Friday, April 24th, that Ricardo Sartim, CEO of the diagnostic medicine company, is leaving the company, which owns brands such as CDB and Multilab.
In addition to being CEO, the executive had been serving as interim CFO since November 2025 and was a member of the company's board of directors. According to the company, he cited personal reasons for making the decision.
In a relevant announcement, Alliança Saúde reported that it has already begun the succession process for the CEO and CFO positions. It also announced the approval of the election of João de Saint Brisson Paes de Carvalho as a new member of the board until the next general meeting to be held by the group.
Sartim's departure is yet another chapter in the turbulent period the company is experiencing. He was appointed to lead the operation exactly one year ago, replacing Isabella Tanure, daughter of Nelson Tanure .
The businessman, in turn, took control of Alliança Saúde in 2022, when the group was still called Alliar, with a strong agenda of inorganic growth. At the time, he offered his stake as collateral to obtain a loan intended for the purchase of Ligga Telecom, acquired in 2020.
In February of this year, however, creditors seized Alliança's shares due to the operation's deteriorating financial situation. The shares were transferred to the Tessai fund, a fund linked to Geribá, a manager specializing in special situations.
At the time, Tanure's departure from control of the operation marked another step in a kind of "fire sale" by the businessman, who, just as with Alliança, saw his stakes in other companies, such as Light and Prio, transferred to meet obligations to creditors.
While still under Tanure's control, Alliança Saúde hired BTG Pactual in December 2025 to advise it on finding alternatives for reorganizing its business, which included a potential sale of the operation, something that did not materialize.
At the end of March, after the businessman left and a precautionary action was filed seeking protection from creditors, the company was granted an injunction allowing it 60 days to suspend foreclosures and the removal of assets essential to its operation.
With net debt of R$ 499.7 million at the end of the third quarter of 2025, Alliança Saúde postponed, at the same time, the release of its fourth-quarter and consolidated year-end financial statements, citing, among other issues, the need to reflect the effects of the start of talks with creditors.
In April, in yet another twist, Alliança reported that Siemens Healthineers had made a unilateral transfer of approximately R$ 11.8 million, which had been deposited in an account linked to a financing agreement between the two parties, in October 2025.
"The measures adopted by Siemens have had a significant impact on the company's short-term liquidity, affecting its ability to promptly meet certain financial obligations, including commitments to suppliers and medical staff," the group stated at the time.
In the relevant fact in question, Alliance highlighted that, even after the granting of the injunction requesting protection of its liquidity, Siemens continued with "new attempts" and adopted judicial and extrajudicial measures for the "isolated and exclusive satisfaction of its credits".
Also in April, in parallel to this imbroglio, the company announced the termination of negotiations for the acquisition of the Meddi Group, a move that was considered extremely strategic for the expansion of its operations, particularly in the Northeast.
Amid this saga, Alliança Saúde's shares have accumulated a devaluation of 53.2% in 12 months, and more than 40% in 2026. The shares closed yesterday's trading session with a drop of 1.96%, quoted at R$ 3, giving the company a market value of R$ 456.9 million.
